Google, Gates-backed Waltham Biotech Hunts a $58M IPO
A biotech co-founded by Adimab’s Tillman Gerngross, Arsanis plots $58M IPO to get its mid-stage pneumonia fighting antibody through Phase II and down the road to a potential approval.
The 39-employee company said in a federal filing that it hopes to raise up to $57.5 million in an initial public offering. It comes six months after Arsanis closed a $45 million Series D round led by the Gates Foundation, which has invested significant sums to fight infectious diseases. Other investors in that round included GV, the venture arm of Google parent company Alphabet, and Boston-based Polaris Partners.
The Waltham, MA-based biotech joins a growing lineup of developers who see the recent slate of successful IPOs as an invitation to raise new sums of cash for their R&D plans.
And it’s conducting research in neonatal Staphylococcus aureus sepsis—an infection that affects newborns in developing countries—with the potential for future funding to advance a neonatal sepsis candidate.
The Gates Foundation, as part of its series D, could also further boost funding to Arsanis for up to two additional
discovery programs.
